Enovis Corp
Enovis Corp operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related products.
Business. Enovis Corp (ENOV.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Analyst recommendations
12 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Enovis Corp (ENOV.K) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot establishes the baseline for tracking future ownership shifts and market interest in the company. The specific change involves a new holder, identified by investor ID 929, who acquired 200,000 shares as of March 31, 2026. This position represents a value of approximately $0.194 million and constitutes a weight of roughly 0.000036% of the total equity, indicating a relatively small but distinct entry into the capital structure. This activity is significant as it contributes to the company's current profile, which includes 25 top holders and one reported officer. With zero analysts currently covering the stock and no index memberships, the emergence of new institutional or significant holders like investor ID 929 may signal early stages of increased visibility or interest in the firm. The detection of this holder change on June 28, 2026, provides a concrete data point for monitoring Enovis Corp's evolving investor landscape. As the company builds its public record, such additions serve as key indicators of how capital is beginning to allocate toward the business amidst its current operational and financial context.
Signals & dispatch
Composite-score breakdown
Synthesis
Enovis Corp (ENOV.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Enovis Corp maintains a capital structure characterized by significant leverage, with long-term debt of $1.26 billion against total equity of $1.49 billion, resulting in a debt-to-equity ratio of 0.85. The company holds only $36.4 million in cash and equivalents, leading to a negative net cash position after subtracting total debt. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied by the balance sheet composition. The market capitalization stands at $1.62 billion, trading at a price-to-book ratio of 1.08, indicating the market values the company close to its tangible book value.
Profitability metrics are severely negative, with a return on equity of -76.3% and a return on assets of -29.7%. The company reported an operating income of -$1.12 billion and a net income of -$1.18 billion for the latest period, despite generating gross profit of $1.35 billion on revenues of $2.25 billion. This indicates substantial operating expenses or restructuring costs eroding the gross margin. The EV/EBITDA ratio is negative at -2.65, reflecting the current loss-making status. Without cohort median data for direct comparison, these returns suggest the company is in a transitional or distressed phase relative to typical industry peers.
Revenue concentration details are not provided in the available segments or geography sections. The company’s total revenue is $2.25 billion, but the specific breakdown by product line or region is absent from the input data. Consequently, the degree of exposure to specific markets or customer bases cannot be quantified from the current snapshot.
Growth trajectory analysis is limited by the absence of historical period data. The latest normalized period shows revenue of $2.25 billion, but without prior year or quarterly comparisons, the direction and velocity of revenue growth cannot be determined. The lack of historical trends prevents an assessment of whether the current revenue base is expanding, contracting, or stable.
Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which constrains financial flexibility. The low dilution risk suggests that the company is not currently issuing significant new shares, with basic and diluted shares outstanding both at 57.2 million. The negative net cash position remains the primary financial constraint, requiring careful management of operating cash flows.
Recent observations include analyst estimates with a mean price target of $41.09 and a median of $40.00, implying a potential upside from the current market price of $28.25. The mean recommendation is 1.75, indicating a strong buy consensus among analysts, with 4 strong buys and 7 buys recorded. News events indicate a reconciler enqueue process for analysis jobs, but no specific corporate actions or material news events are disclosed in the observations.
Enovis Corp (ENOV.K) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot establishes the baseline for tracking future ownership shifts and market interest in the company. The specific change involves a new holder, identified by investor ID 929, who acquired 200,000 shares as of March 31, 2026. This position represents a value of approximately $0.194 million and constitutes a weight of roughly 0.000036% of the total equity, indicating a relatively small but distinct entry into the capital structure. This activity is significant as it contributes to the company's current profile, which includes 25 top holders and one reported officer. With zero analysts currently covering the stock and no index memberships, the emergence of new institutional or significant holders like investor ID 929 may signal early stages of increased visibility or interest in the firm. The detection of this holder change on June 28, 2026, provides a concrete data point for monitoring Enovis Corp's evolving investor landscape. As the company builds its public record, such additions serve as key indicators of how capital is beginning to allocate toward the business amidst its current operational and financial context.
- Enovis Corp reports significant net losses of $1.18 billion, driven by operating expenses exceeding gross profit of $1.35 billion.
- The company carries $1.26 billion in long-term debt with only $36.4 million in cash, resulting in a negative net cash position.
- Analyst sentiment is positive, with a mean recommendation of 1.75 and a mean price target of $41.09, suggesting expected future improvement.
- Return on equity is -76.3%, indicating severe erosion of shareholder value in the current period.
- Dilution risk is low, with no difference between basic and diluted shares outstanding.
Bull / Bear case
Generated · model-assistedRevenue grew 12% annually over four years, reaching $2.25 billion in fiscal 2026, demonstrating consistent top-line expansion.
Analysts project 45.5% upside to a mean price target of $41.09, reflecting strong institutional confidence in future performance.
Gross profit increased to $1.31 billion in fiscal 2026, indicating improving operational efficiency and product margin strength.
The company maintains a current ratio of 2.02, suggesting sufficient short-term liquidity to cover immediate operational obligations.
Dilution risk is assessed as low, providing reassurance to existing shareholders regarding potential equity value erosion.
Interest coverage is negative at -32.3x, highlighting an inability to service debt obligations from current operating earnings.
In focus — financials by report
Revenue $589.2M, +5,4% YoY; Operating income +114,0% YoY.
- ▍Revenue $589.2M, +5,4% YoY
- ▍Operating income +114,0% YoY
- ▍Net income +84,3% YoY
- ▍Free cash flow +144,3% YoY
- ▍Net margin -1.5%
Revenue $575.8M, +2,6% YoY; Operating income +24,5% YoY.
- ▍Revenue $575.8M, +2,6% YoY
- ▍Operating income +24,5% YoY
- ▍Net income +26,0% YoY
- ▍Free cash flow +27,0% YoY
- ▍Net margin -90.4%
Revenue $548.9M, +8,7% YoY; Operating income −1 659,7% YoY.
- ▍Revenue $548.9M, +8,7% YoY
- ▍Operating income −1 659,7% YoY
- ▍Net income −1 712,0% YoY
- ▍Free cash flow −3 983,9% YoY
- ▍Net margin -104.1%
Revenue $564.5M, +7,5% YoY; Operating income +58,0% YoY.
- ▍Revenue $564.5M, +7,5% YoY
- ▍Operating income +58,0% YoY
- ▍Net income −97,1% YoY
- ▍Free cash flow −217,2% YoY
- ▍Net margin -6.5%
Revenue $558.8M; Operating income -$46.8M.
- ▍Revenue $558.8M
- ▍Operating income -$46.8M
- ▍Net margin -10.0%
Revenue $561.0M; Operating income -$664.7M.
- ▍Revenue $561.0M
- ▍Operating income -$664.7M
- ▍Net margin -125.4%
Revenue $505.2M; Operating income -$31.7M.
- ▍Revenue $505.2M
- ▍Operating income -$31.7M
- ▍Net margin -6.2%
Revenue $525.2M; Operating income -$44.2M.
- ▍Revenue $525.2M
- ▍Operating income -$44.2M
- ▍Net margin -3.5%
Revenue $2.25B, +6,7% YoY; Operating income −45,2% YoY.
- ▍Revenue $2.25B, +6,7% YoY
- ▍Operating income −45,2% YoY
- ▍Net income −43,5% YoY
- ▍Free cash flow −50,0% YoY
- ▍Net margin -52.7%
Revenue $2.11B, +23,5% YoY; Operating income −962,0% YoY.
- ▍Revenue $2.11B, +23,5% YoY
- ▍Operating income −962,0% YoY
- ▍Net income −2 381,9% YoY
- ▍Free cash flow −1 862,0% YoY
- ▍Net margin -39.2%
Revenue $1.71B, +9,2% YoY; Operating income +20,2% YoY.
- ▍Revenue $1.71B, +9,2% YoY
- ▍Operating income +20,2% YoY
- ▍Net income −150,2% YoY
- ▍Free cash flow −77,9% YoY
- ▍Net margin -1.9%
Revenue $1.56B, +9,6% YoY; Operating income +1,2% YoY.
- ▍Revenue $1.56B, +9,6% YoY
- ▍Operating income +1,2% YoY
- ▍Net income −118,5% YoY
- ▍Free cash flow +228,8% YoY
- ▍Net margin -0.9%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3,65 |
| Revenue | —no estimate | —no estimate | 2,3B USD |
| Operating income | —no estimate | —no estimate | 284,1M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Enovis CORP Market data — financials · 2026-07-28
- reconciler_enqueue (reconciler) on ENOV.K · 2026-07-28
- Enovis Corp Market data — analyst estimates · 2026-07-28
- Enovis Corp Market data — ESG · 2026-07-28
- Enovis Corp HA canonical relationships · 2026-07-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,06 %$108M
- Investment Managers · as of 2026-03-310,01 %$58M
- Investment Managers · as of 2024-06-300,01 %$245M
- Investment Managers · as of 2026-03-310,00 %$36M
- Institutional Investor · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$23M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$10M
- Investment Managers · as of 2025-12-310,00 %$172M
- Investment Managers · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$14M
- Institutional Investor · as of 2026-03-310,00 %$31M
- Brokerage Firms · as of 2026-03-310,00 %$5M
- Funds · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Matthew L. TrerotolaChairman of the Board, Chief Executive Officer
Insider activity
- Director · Common stock, par value $0.001Other 846 · 2026-06-30
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $20,92$21K · 2026-06-15
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $21,75$22K · 2026-06-11
- Chief Administrative Officer · Common stock, par value $0.001Bought 200 @ $20,99$4K · 2026-06-11
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,00$23K · 2026-06-10
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $22,22$22K · 2026-06-01
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
- Director, Chief Executive Officer · Common stock, par value $0.001Other 12 634 @ $25,99$328K · 2026-05-12
- SVP, Chief Financial Officer · Common stock, par value $0.001Other 7 774 @ $25,99$202K · 2026-05-12
- Director · Common stock, par value $0.001Other 770 · 2026-03-31
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,74$24K · 2026-03-13
- Chief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,93$24K · 2026-03-10
- SVP, Chief HR Officer · Common stock, par value $0.001Other 25 586 · 2026-03-09
- GROUP PRESIDENT, RECON · Common stock, par value $0.001Other 36 247 · 2026-03-09
- Principal Accounting Officer · Common stock, par value $0.001Other 14 925 · 2026-03-09
- SVP and Chief Legal Officer · Common stock, par value $0.001Other 25 586 · 2026-03-09
- GROUP PRESIDENT, P&R · Common stock, par value $0.001Other 36 247 · 2026-03-09
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 36.39MUnknown
- Shares outstanding (annual): 57.19MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -21Unknown
- Gross profit (annual): USD 1.35BUnknown
- Pre-tax income (annual): USD -1.16BUnknown
- Capex (annual): USD 197.38MUnknown
- Shareholders' equity (annual): USD 1.49BUnknown
- Total liabilities (annual): USD 2.34BUnknown
- Operating income (annual): USD -1.12BUnknown
- Current assets (annual): USD 1.21BUnknown
- Current liabilities (annual): USD 598.47MUnknown
- EPS (basic) (annual): USD-PER-SHARES -21Unknown
- Interest expense (annual): USD 34.82MUnknown
- Operating cash flow (annual): USD 217.29MUnknown
- R&D expense (annual): USD 120.33MUnknown
- Revenue (annual): USD 2.25BUnknown
- Cost of revenue (annual): USD 902.79MUnknown
- Net income (annual): USD -1.18BUnknown
- Total assets (annual): USD 3.83BUnknown
- Long-term debt (annual): USD 1.3BUnknown
- Current assets (annual): USD 1.15BUnknown
- EPS (diluted) (annual): USD-PER-SHARES -15Unknown
- Current liabilities (annual): USD 529MUnknown
- Operating cash flow (annual): USD 113.5MUnknown